#USA #London #T Cell Therapy #Swarm Oncology #Cellex

Swarm and Cellex Form Strategic Alliance

In a significant move to enhance cancer treatment methods, Swarm Oncology Ltd., a biotechnology innovator focused on T cell therapies for solid tumors, has announced a strategic partnership with Cellex Cell Professionals GmbH. This collaboration is set to expedite vital processes in the manufacturing and clinical development of novel T cell therapies.

The Need for Innovative Solutions

Despite strides in oncology, data shows that over 82% of patients suffering from advanced metastatic cancer succumb to the disease. Current immunotherapies often provide limited survival benefits due to several challenges, including T cell exhaustion and insufficient quantities of effective therapy cells. To address these challenges, Swarm’s unique platform, known as Swarm-T, integrates in vivo immune preparation with patented ex vivo manufacturing techniques to produce highly potent, polyclonal, and non-exhausted T cells. By doing so, it aims to provide a sustained and powerful immune attack against solid tumors, moving away from traditional limitations.

A Brief Overview of the Partnership

Under this agreement, Cellex will play a crucial role by supplying starting cell materials and overseeing process transfers, adhering to Good Manufacturing Practices (GMP), and ensuring rigorous quality control. Furthermore, Cellex is equipped to support regulatory compliance and provide specialized infrastructure to facilitate the progression of Swarm’s therapies towards clinical trials by 2026. The overarching goal is to expedite clinical timelines, mitigate manufacturing bottlenecks, and enhance scalability, paving the way for these cutting-edge T cell therapies to reach patients in urgent need.

Perspectives from Leadership

Martin Olin, CEO of Swarm Oncology, expressed, "Our mission is to revolutionize immunotherapy by overcoming existing limitations and achieving long-term remission for solid tumors. With Cellex’s extensive experience in cell procurement, therapy manufacturing, and regulatory compliance, we can ensure a high-quality, seamless manufacturing process, propelling our clinical development forward."

Professor Dr. Gerhard Ehninger, CEO of Cellex, added, "We are excited to contribute to Swarm's innovative efforts in treating solid cancers. With state-of-the-art facilities and over ten years of experience in T cell therapy production, our collaboration places us in a unique position to advance these transformative therapies more efficiently into clinical settings."

Company Backgrounds

Swarm Oncology: Founded by renowned T cell therapy expert Professor John Campbell and Delin Ventures, Swarm specializes in powerful and innovative T cell therapies aimed at achieving complete remission for solid cancers. Their goal is to address the critical weaknesses present in current immunotherapy approaches. For more details, visit www.swarmoncology.bio.

Cellex Cell Professionals: A CDMO powerhouse specializing in cell and gene therapy, Cellex brings over a decade of experience in both autologous and allogeneic cell therapy development. With cutting-edge facilities in Cologne, Germany, Cellex is deeply involved in clinical and commercial manufacturing, ensuring compliance with stringent regulatory standards. More information can be found at www.cellex.me/en.

Both companies are committed to pushing the envelope in cancer treatment, utilizing their respective expertise to enhance the manufacturing and application of T cell therapies, ultimately aiming for a new tier of cancer care that could change lives for patients fighting solid tumors.